<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011725</url>
  </required_header>
  <id_info>
    <org_study_id>0773-003</org_study_id>
    <secondary_id>MK0773-003</secondary_id>
    <nct_id>NCT01011725</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Efficacy of MK0773 in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic
      efficacy of MK0773 in healthy postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Serious Clinical Adverse Events</measure>
    <time_frame>From date of enrollment through 12 weeks of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Nonerserious Clinical Adverse Events</measure>
    <time_frame>From date of enrollment through 12 weeks of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious Laboratory Adverse Events</measure>
    <time_frame>From date of enrollment through 12 weeks of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Nonserious Laboratory Adverse Events</measure>
    <time_frame>From date of enrollment through 12 weeks of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Due to Any Adverse Event</measure>
    <time_frame>From date of enrollment through 12 weeks of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Withdrew Consent and Discontinued the Study</measure>
    <time_frame>From date of enrollment through 12 weeks of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Least Squares Mean Change in Lean Body Mass</measure>
    <time_frame>From baseline, at 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Postmenopausal Women- Active Agent Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Postmenopausal Women- Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK 0773</intervention_name>
    <description>25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks</description>
    <arm_group_label>Postmenopausal Women- Active Agent Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral tablet b.i.d for 12 weeks</description>
    <arm_group_label>Postmenopausal Women- Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a nonsurgical postmenopausal female

          -  Subject is neither grossly overweight nor underweight for her height

          -  Subject is in good health

          -  Subject is willing to avoid excess alcohol and strenuous physical activity during the
             study

          -  Subject agrees to refrain from consuming St. John's Wort, grapefruit or grapefruit
             juice during the study

        Exclusion Criteria:

          -  Subject has significant drug allergies

          -  Subject has donated blood or taken an investigational drug in another clinical trial
             within the last 4 weeks

          -  Subject is a regular user or past abuser of any illicit drug (including alcohol)

          -  Subject drinks excessive amounts of caffeinated beverages

          -  Subject has a history of cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>August 9, 2016</last_update_submitted>
  <last_update_submitted_qc>August 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

